Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register allows you to search for protocol and results information on:
  • interventional clinical trials that are conducted in the European Union (EU) and the European Economic Area (EEA);
  • clinical trials conducted outside the EU / EEA that are linked to European paediatric-medicine development.
  • Learn   more about the EU Clinical Trials Register   including the source of the information and the legal basis.


    The EU Clinical Trials Register currently displays   42330   clinical trials with a EudraCT protocol, of which   6971   are clinical trials conducted with subjects less than 18 years old.
    The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).


    Phase 1 trials conducted solely in adults and that are not part of an agreed PIP are not public in the EU CTR (refer to European Guidance 2008/C 168/02   Art. 3 par. 2 and   Commission Guideline 2012/C 302/03,   Art. 5) .

    Clinical Trials marked as "Trial now transitioned" were transitioned to the Clinical Trial Regulation 536/2014 and can be further followed in the Clinical Trial Information System  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2008-002708-25
    Sponsor's Protocol Code Number:RIVAROXACS3001(BAY59-7939/13194)
    National Competent Authority:Germany - BfArM
    Clinical Trial Type:EEA CTA
    Trial Status:Completed
    Date on which this record was first entered in the EudraCT database:2008-10-30
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedGermany - BfArM
    A.2EudraCT number2008-002708-25
    A.3Full title of the trial
    A Randomized, Double-Blind, Placebo-Controlled, Event-Driven Multicenter Study to Evaluate the Efficacy and Safety of Rivaroxaban in Subjects with a Recent Acute Coronary Syndrome

    The ATLAS ACS 2 TIMI 51 Trial (The second trial of Anti-Xa Therapy to Lower cardiovascular events in Addition to standard therapy in Subjects with Acute Coronary Syndrome)

    Amendment INT-2
    A.3.2Name or abbreviated title of the trial where available
    The ATLAS ACS 2 TIMI 51 Trial
    A.4.1Sponsor's protocol code numberRIVAROXACS3001(BAY59-7939/13194)
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorJanssen-Cilag International N.V.
    B.1.3.4CountryBelgium
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing support
    B.4.2Country
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationBayer HealthCare AG
    B.5.2Functional name of contact pointCTP Team/Ref:"EU CTR"/
    B.5.3 Address:
    B.5.3.1Street AddressBayer Pharma AG S102, Level 2, Room 156
    B.5.3.2Town/ cityBerlin
    B.5.3.3Post code13342
    B.5.3.4CountryGermany
    B.5.6E-mailclinical-trials-contact@bayerhealthcare.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameRivaroxaban
    D.3.2Product code Bay 59-7939 (JNJ-39039039)
    D.3.4Pharmaceutical form Film-coated tablet
    D.3.4.1Specific paediatric formulation Information not present in EudraCT
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNRivaroxaban
    D.3.9.1CAS number 366789-02-8
    D.3.9.2Current sponsor codeBAY 59-7939 (JNJ-39039039)
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number2.5
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) Information not present in EudraCT
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy Information not present in EudraCT
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Information not present in EudraCT
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameRivaroxaban
    D.3.2Product code Bay 59-7939 (JNJ-39039039)
    D.3.4Pharmaceutical form Film-coated tablet
    D.3.4.1Specific paediatric formulation Information not present in EudraCT
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNRivaroxaban
    D.3.9.1CAS number 366789-02-8
    D.3.9.2Current sponsor codeBay 59-7939 (JNJ-39039039)
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number5.0
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) Information not present in EudraCT
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy Information not present in EudraCT
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Information not present in EudraCT
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboFilm-coated tablet
    D.8.4Route of administration of the placeboOral use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Acute Coronary Syndrome (ACS)
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 14.0
    E.1.2Level PT
    E.1.2Classification code 10051592
    E.1.2Term Acute coronary syndrome
    E.1.2System Organ Class 10007541 - Cardiac disorders
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    The primary objective of the study is to determine whether rivaroxaban in addition to standard care reduces the risk of the composite of cardiovascular (CV) death, myocardial infarction (MI), or stroke in subjects with a recent ACS compared with placebo in addition to standard care.
    E.2.2Secondary objectives of the trial
    • To determine whether rivaroxaban reduces the risk of the composite of all cause death, MI, or stroke in subjects with a recent ACS compared with placebo in addition to standard care
    • To examine the effect of rivaroxaban on net clinical outcome, defined as the composite of CV death, MI, ischemic stroke, or a Thrombolysis in Myocardial Infarction (TIMI) major bleeding event not associated with coronary artery bypass graft (CABG) surgery
    • To determine whether rivaroxaban reduces the risk of the composite of CV death, MI, stroke, or severe recurrent ischemia requiring revascularization in subjects with a recent ACS compared with placebo in addition to standard care
    • To determine whether rivaroxaban reduces the risk of the composite of CV death, MI, stroke, or severe recurrent ischemia leading to hospitalization in subjects with a recent ACS compared with placebo in addition to standard care
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    Potential subjects must satisfy the following criteria to be enrolled in the study:
    • Man or woman 18 years of age or older
    • Currently receiving ASA therapy (75 to 100 mg/day) alone or in combination with a thienopyridine (clopidogrel
    or ticlopidine per national dosing recommendation)
    • Have been hospitalized for symptoms suggestive of ACS that lasted at least 10 minutes at rest, and occurred 48
    hours or less before hospital presentation or who develop ACS while being hospitalized for an indication other
    than ACS, and have a diagnosis of:
    - STEMI:
    - elevation of ST-segment more than 0.1 millivolt (mV) in 2 or more continuous ECG leads, or new left bundle
    branch block, or ST segment depression 0.1 mV or greater in 2 of the precordial leads V1 V4 with evidence
    suggestive of true posterior infarction, all with elevated biomarkers of myocardial necrosis (creatinine kinase
    muscle and brain isoenzyme [CK-MB] or troponin)
    - NSTEMI:
    - Elevated biomarkers of myocardial necrosis (creatinine kinase-muscle and brain isoenzyme [CK-MB] or
    troponin) plus 1 of the following:
    - Transient ST-segment elevation, or ST-segment depression, or T-wave changes consistent with myocardial
    ischemia
    or
    - Identification of a culprit lesion at coronary angiography demonstrating recent, active intracoronary athero
    thrombosis (for example, thrombus or an ulcerated plaque
    - UA with at least 1 of the following:
    - transient or persistent ST-segment deviation 0.1 mV or greater in 1 or more ECG leads OR
    - TIMI risk score of ≥4
    • Subjects who are 18 to 54 years of age inclusive must also have either diabetes mellitus or a prior MI in addition
    to the presenting ACS event.
    • Women must be:
    – postmenopausal (for at least 2 years), or
    – surgically sterile, (have had a hysterectomy or bilateral oophorectomy, tubal ligation, or otherwise be
    incapable of pregnancy), or
    – abstinent (at the discretion of the investigator/per local regulations), or
    – if sexually active, be practicing an effective method of birth control (e.g., prescription oral contraceptives,
    contraceptive injections, contraceptive patch, intrauterine device, double-barrier method, male partner
    sterilization) as local regulations permit, before entry, and must agree to continue to use the same method of
    contraception throughout the study.
    • Women of childbearing potential must have a negative urine β-human chorionic gonadotropin (β-hCG)
    pregnancy test at screening. Serum pregnancy testing may be performed if required by local regulation.
    • Subjects must have signed an informed consent document indicating that they understand the purpose of and
    procedures required for the study and are willing to participate in the study.
    E.4Principal exclusion criteria
    Bleeding risk
    • Any condition that, in the opinion of the investigator, contraindicates anticoagulant therapy or would have an
    unacceptable risk of bleeding, such as, but not limited to, the following:
    – active internal bleeding, clinically significant bleeding, bleeding at a noncompressible site, or bleeding diathesis
    within 30 days of randomization
    – platelet count <90,000/μL at screening
    – history of intracranial hemorrhage
    – major surgery, biopsy of a parenchymal organ, or serious trauma within 30 days before randomization
    – clinically significant gastrointestinal bleeding within 12 months before randomization
    – have an International Normalized Ratio (INR) known to be >1.5 at the time of screening
    – abciximab bolus or infusion within the past 8 hours, or an eptifibatide or tirofiban bolus or infusion within the
    past 2 hours before randomization
    – any other condition known to increase the risk of bleeding
    Severe concomitant diseases such as:
    • Cardiogenic shock at the time of randomization
    • Ventricular arrhythmias refractory to treatment at the time of randomization
    • Calculated creatinine clearance <30 mL/min at screening
    • Known significant liver disease (e.g., acute hepatitis, chronic active hepatitis, cirrhosis), or liver function test
    (LFT) abnormalities (confirmed with repeat testing) which would require study drug discontinuation, i.e., ALT
    >5 x ULN or ALT >3 x ULN plus total bilirubin >2 x ULN
    • A prior ischemic stroke or TIA in subjects who are planned to be included in stratum 2 (ASA plus
    thienopyridine). (Note: Subjects with a prior ischemic stroke or TIA are eligible for inclusion in the study
    only if they are intended to be treated with ASA only). Subjects with a prior hemorrhagic stroke are excluded
    completely from the study.
    • Anemia (i.e., hemoglobin <10 g/dL) at screening
    • Known clinical history of HIV infection at screening
    • Substance abuse (drug or alcohol) problem within the previous 6 months
    • Any severe condition that would limit life expectancy to less than 6 months
    General:
    • Systemic treatment with strong CYP 3A4 and P-gp inhibitors (e.g., certain azoleantimycotics, such as
    ketoconazole and HIV protease inhibitors, such as ritonavir). These active substances are strong inhibitors of
    both CYP3A4 and P-gp.
    •Allergy or hypersensitivity to any component of rivaroxaban or placebo excipients (includes lactose,
    microcrystalline cellulose, magnesium stearate, hypromellose, macrogol, croscarmellose sodium, sodium lauryl
    sulfate, titanium oxide)
    • Known aspirin allergy
    • Atrial fibrillation excluded except for subjects younger than 60 years of age who have no clinical or
    echocardiographic evidence of cardiopulmonary disease and who had only a single episode of atrial fibrillation
    that occurred more than 2 years ago.
    •Other conditions requiring long-term anticoagulation
    • Use of disallowed therapies (see Section 8, Prestudy and Concomitant Therapy)
    • Received an investigational drug or used an investigational medical device within 30 days before the planned
    start of treatment, or are currently enrolled in an investigational study
    • Anticipated need for chronic (more than 4 weeks) therapy with non steroidal anti-inflammatory drugs (NSAIDs)
    • Is pregnant or breast-feeding or planning to become pregnant during the study
    • Have previously completed or withdrawn from this study
    • Any condition that, in the opinion of the investigator, would compromise the well-being of the subject or the
    study or prevent the subject from meeting or performing study requirements
    • Employees of the investigator or study center, with direct involvement in the proposed study or other studies
    under the direction of that investigator or study center, as well as family members of the employees or the
    investigator
    E.5 End points
    E.5.1Primary end point(s)
    The primary objective of the study is to determine whether rivaroxaban in addition to standard care reduces the risk of the composite of CV death, MI, or stroke in subjects with a recent ACS compared with placebo in addition to standard care.
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy No
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic No
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo Yes
    E.8.2.3Other No
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA400
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA Information not present in EudraCT
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years3
    E.8.9.1In the Member State concerned months0
    E.8.9.1In the Member State concerned days
    E.8.9.2In all countries concerned by the trial years3
    E.8.9.2In all countries concerned by the trial months0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero Information not present in EudraCT
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) Information not present in EudraCT
    F.1.1.3Newborns (0-27 days) Information not present in EudraCT
    F.1.1.4Infants and toddlers (28 days-23 months) Information not present in EudraCT
    F.1.1.5Children (2-11years) Information not present in EudraCT
    F.1.1.6Adolescents (12-17 years) Information not present in EudraCT
    F.1.2Adults (18-64 years) Yes
    F.1.3Elderly (>=65 years) Yes
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state250
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 7000
    F.4.2.2In the whole clinical trial 16000
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2008-12-19
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2009-03-13
    P. End of Trial
    P.End of Trial StatusCompleted
    P.Date of the global end of the trial2011-09-19
    For support, visit the EMA Service Desk , log in using your EMA account and open a ticket specifying "EU CTR" in your request.
    If you do not have an account, please visit the EMA Account management page page click on "Create an EMA account" and follow the instructions.
    The status of studies in GB is no longer updated from 1.1.2021
    For the UK, as from 1.1.2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI
    EU Clinical Trials Register Service Desk: https://servicedesk.ema.europa.eu
    European Medicines Agency © 1995-2022 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    Legal notice
    EMA HMA